JP2011513310A5 - - Google Patents

Download PDF

Info

Publication number
JP2011513310A5
JP2011513310A5 JP2010548749A JP2010548749A JP2011513310A5 JP 2011513310 A5 JP2011513310 A5 JP 2011513310A5 JP 2010548749 A JP2010548749 A JP 2010548749A JP 2010548749 A JP2010548749 A JP 2010548749A JP 2011513310 A5 JP2011513310 A5 JP 2011513310A5
Authority
JP
Japan
Prior art keywords
ggf2
composition
amount
myelination
jun
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010548749A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011513310A (ja
JP5697455B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/001356 external-priority patent/WO2009108390A2/en
Publication of JP2011513310A publication Critical patent/JP2011513310A/ja
Publication of JP2011513310A5 publication Critical patent/JP2011513310A5/ja
Application granted granted Critical
Publication of JP5697455B2 publication Critical patent/JP5697455B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010548749A 2008-02-29 2009-03-02 グリア成長因子２の所望の血漿レベルを達成するための方法 Expired - Fee Related JP5697455B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6758908P 2008-02-29 2008-02-29
US61/067,589 2008-02-29
PCT/US2009/001356 WO2009108390A2 (en) 2008-02-29 2009-03-02 Method for achieving desired glial growth factor 2 plasma levels

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014212193A Division JP5964920B2 (ja) 2008-02-29 2014-10-17 グリア成長因子２の所望の血漿レベルを達成するための方法

Publications (3)

Publication Number Publication Date
JP2011513310A JP2011513310A (ja) 2011-04-28
JP2011513310A5 true JP2011513310A5 (enExample) 2012-04-19
JP5697455B2 JP5697455B2 (ja) 2015-04-08

Family

ID=41016663

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010548749A Expired - Fee Related JP5697455B2 (ja) 2008-02-29 2009-03-02 グリア成長因子２の所望の血漿レベルを達成するための方法
JP2014212193A Expired - Fee Related JP5964920B2 (ja) 2008-02-29 2014-10-17 グリア成長因子２の所望の血漿レベルを達成するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014212193A Expired - Fee Related JP5964920B2 (ja) 2008-02-29 2014-10-17 グリア成長因子２の所望の血漿レベルを達成するための方法

Country Status (11)

Country Link
US (5) US8410050B2 (enExample)
EP (3) EP3120863B1 (enExample)
JP (2) JP5697455B2 (enExample)
CN (2) CN102026651B (enExample)
AU (1) AU2009217606B2 (enExample)
BR (1) BRPI0908271A2 (enExample)
CA (1) CA2717193C (enExample)
ES (2) ES2811127T3 (enExample)
PL (2) PL3120863T3 (enExample)
RU (3) RU2530650C2 (enExample)
WO (1) WO2009108390A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102026651B (zh) 2008-02-29 2015-06-03 阿索尔达治疗公司 达到所需胶质生长因子2血浆水平的方法
EP3338791B1 (en) 2008-07-17 2019-09-18 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin in the treatment or prophylaxis of heart failure
CN104707130A (zh) 2008-08-15 2015-06-17 阿索尔达治疗公司 在cns神经性损伤后非-急性期间处理的组合物及方法
AU2010306777C1 (en) 2009-10-14 2016-03-17 Acorda Therapeutics, Inc. Use of a neuregulin to treat peripheral nerve injury
WO2011147981A2 (en) * 2010-05-28 2011-12-01 Mind-Nrg Sa Neuregulin isoforms, neuregulin polypeptides and uses thereof
WO2012021818A2 (en) * 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use
WO2013149163A1 (en) * 2012-03-30 2013-10-03 Acorda Therapeutics, Inc. Use of neuregulin to treat peripheral nerve injury
WO2018056412A1 (ja) * 2016-09-23 2018-03-29 国立大学法人大阪大学 シュワン細胞分化促進剤及び末梢神経再生促進剤
CN108653274B (zh) * 2017-04-01 2022-09-16 鲁南制药集团股份有限公司 牛蒡子苷元在制备治疗骨髓损伤药物中的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7319019B1 (en) 1991-04-10 2008-01-15 Acorda Therapeutics, Inc. Glial mitogenic factors lacking an N-terminal signal sequence
US7135456B1 (en) 1991-04-10 2006-11-14 Acorda Therapeutics, Inc. Glial mitogenic factors, their preparation and use
US7037888B1 (en) * 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
GB9217316D0 (en) 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
AU3003701A (en) * 1999-11-19 2001-05-30 Axxima Pharmaceuticals Ag Inhibitors of helicobacter pylori induced gastrointestinal diseases
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
MX351062B (es) * 2003-05-16 2017-09-29 Acorda Therapeutics Inc Proteinas de fusion para el tratamiento del snc.
WO2005079458A2 (en) * 2004-02-19 2005-09-01 The Regents Of The University Of California ENHANCEMENT OF Th2-DEPENDENT AND INFLAMMATORY RESPONSE
AU2006210537A1 (en) 2005-02-02 2006-08-10 Fox Chase Cencer Center Amine derivative containing compositions and methods for the treatment of viral infections related to the etiology of cancer
CA2658326C (en) 2005-09-02 2013-04-23 Morehouse School Of Medicine Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue
US20080003013A1 (en) * 2006-06-30 2008-01-03 Static Control Components, Inc. Cartridge split rail clip
CN102026651B (zh) * 2008-02-29 2015-06-03 阿索尔达治疗公司 达到所需胶质生长因子2血浆水平的方法
WO2011123606A1 (en) 2010-04-01 2011-10-06 The Procter & Gamble Company Fabric softener
WO2012021818A2 (en) 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use

Similar Documents

Publication Publication Date Title
Rentzos et al. Serum uric acid and multiple sclerosis
Dicpinigaitis Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines
RU2014131265A (ru) Способ обеспечения требуемых уровней фактора 2 роста глии в плазме
WO2016139475A1 (en) Angiotensin ii receptor agonist for treating pulmonary fibrosis
RU2015110240A (ru) Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия
JP7021298B2 (ja) Ｌ－４－クロロキヌレニンの剤形及び治療的使用
JP6145778B2 (ja) 特発性炎症性筋疾患の予防又は治療剤
KR20090034810A (ko) 멜라토닌 효능제 치료
WO2011028794A2 (en) Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
CN107949379A (zh) L‑4‑氯代犬尿氨酸的治疗用途
JP2013543004A5 (enExample)
KR20190044667A (ko) Fxr 작용제의 신규 요법
TW201204360A (en) Treatment of multiple sclerosis with MASITINIB
Samborski et al. Intra‐articular treatment of arthritides and activated osteoarthritis with the 5‐HT3 receptor antagonist tropisetron. A double‐blind study compared with methylprednisolone
JP6328856B2 (ja) 収縮力低下随伴性排尿筋過活動改善剤
CN110325214A (zh) 用于预防和治疗神经元损伤的低剂量药物组合
US20210161912A1 (en) Peripherally-restricted dual-acting kappa and delta opioid agonist for analgesia in pain states involving the inflammatory response
HK40064613A (en) Methods for treating cancer
CN102149389A (zh) 生物素化艾屈肝素用于降低抗血栓治疗期间出血发生率的用途
Xin et al. Zhengzhou University, Zhengzhou, China
HK40022228A (en) Dosage forms and therapeutic uses l-4- chlorokynurenine
WO2014058786A2 (en) Prevention of kidney injury or disease
Althobaiti Effects of Modulating Glutamate Homeostasis in Methamphetamine and Alcohol Co-Abuse: Potential Therapeutic Targets
Skotnikov et al. FEATURES OF TREATMENT AND PROGNOSIS OF NON-ST ELEVATION ACUTE CORONARY SYNDROME IN PATIENTS WITH IRON DEFICIENCY ANEMIA: PP. 15.426